SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are surging following the announcement that its personalized cancer vaccine successfully met primary endpoints in a Phase 3 trial for melanoma patients. The news has sparked significant community excitement, with investors discussing the stock's long-term potential in oncology and observing a strong reaction across the broader biotech sector.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending following a significant partnership announcement with Google involving a multi-billion dollar custom silicon development deal and a major warrant issuance. The community is actively debating the long-term bullish implications of this AI chip collaboration against concerns regarding share dilution and the stock's recent price volatility.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is facing selling pressure as investors react to concerns over off-balance-sheet financing obligations and market speculation regarding supply chain shifts in the custom AI chip space. Despite the volatility, the community is actively debating whether this decline represents a manipulative shakeout or a strategic buying opportunity for a firm with strong long-term AI infrastructure fundamentals.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck ($MRK) and Moderna ($MRNA) shares are trending following the announcement that their personalized mRNA cancer vaccine, in combination with Keytruda, successfully met primary and secondary endpoints in a late-stage Phase 3 melanoma trial. The broader community is buzzing about this validation of mRNA-based cancer immunotherapy, which is driving significant sympathy interest across the biotech, oncology, and vaccine sectors as investors look for the next breakthrough companies in the cancer-vaccine space.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber shares are experiencing significant volatility following the announcement of a $270 million convertible senior notes offering, which has sparked concerns regarding shareholder dilution despite the company's focus on expanding its data center footprint. Investors are actively debating whether this pullback represents an overreaction to the financing move or a legitimate structural concern, with many community members highlighting the stock as a potential buying opportunity while others express skepticism regarding the company's long-term capital strategy.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

Biotech stocks are surging, primarily driven by strong clinical trial results for mRNA cancer vaccines and other breakthrough treatments. Investors are closely tracking institutional accumulation and sector rotation, fueling significant community interest in potential M&A activity and long-term valuation upside.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending as investors react to a double beat in quarterly earnings and raised full-year guidance that highlights successful turnaround efforts, despite a volatile market response. The community is actively debating the sustainability of these gains, weighing the impact of one-time tariff refunds against mixed category performance and broader consumer spending trends.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing intense volatility and heightened investor interest driven by a strategic $1.5 billion acquisition of Personalis, aimed at expanding its footprint in the AI-powered oncology and cancer monitoring market. The community remains sharply divided, with bulls pointing to institutional accumulation and high short interest as potential catalysts for a squeeze, while bears highlight concerns over insider selling and the financial risks of merger integration.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is surging as investors look past short-term melanoma competition, focusing instead on the company's established commercial TIL platform and high-impact pipeline milestones. The community is actively discussing the stock's transition toward significant growth catalysts, including upcoming lung cancer clinical data and anticipated upward guidance revisions.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors monitor the potential impact of recent breakthroughs in the cancer vaccine sector, fueling discussions about a possible acquisition and an imminent phase 3 data readout. The community remains focused on the potential for a massive valuation re-rating, contrasting bullish expectations for the GPS platform against ongoing debates regarding trial design and modeling scenarios.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TDAC Announces ProLogium's Filing of F-4 As Continuing Momentum Towards Merger

TDAC Announces ProLogium's Filing of F-4 As Continuing Momentum Towards Merger TDAC Announces ProLogium's Filing of F-4 As Continuing Momentum Towards Merger PR Newswire NEW YORK, July 6, 2026 NEW YORK, July 6, 2026 /PRNewswire/ --Translational Development Acquisition Company (NYSE: TDAC) ( "TDAC...

TDAC Announces Very Successful Share Redemption Results in Connection with Extension Vote

TDAC Announces Very Successful Share Redemption Results in Connection with Extension Vote TDAC Announces Very Successful Share Redemption Results in Connection with Extension Vote PR Newswire NEW YORK, June 22, 2026 85% of Shares are not Redeemed, resulting in TDAC maintaining $156.8mm in trust95...

Translational Development Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on April 19, 2022 and is headquartered in New York, NY.

Translational Development Acquisition Corp. - Ordinary Shares- Class A

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$10.85
Prev Close	$10.85
Open	$10.89
Dividend Yield	0.00%
50-Day Moving Average	$10.76
Beta	0.22
Avg. Volume	24,790.39
PE Ratio	42.80

52-Week High	$10.95
52-Week Low	$10.32
Market Capitalization	$260.03M
EPS (Annual)	$0.2904
Price to Book	1.40
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info